newsfilter
← Latest News
GlobeNewswire·

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated –– Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 –– Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022